

Amendments to the Claims:

1.-4. (Canceled)

5. (Previously presented) The vaccine of claim 15, wherein said vaccine when administered elicits an antibody that protects against pneumococcal infection in a mammal.

6. (Original) The vaccine of claim 5 wherein said mammal is a human.

7. (Previously presented) The vaccine of claim 15, wherein said vaccine further comprises an adjuvant.

8.-14. (Canceled)

15. (Previously presented) A vaccine for treating or protecting against pneumococcal infection comprising a polypeptide in a pharmaceutically acceptable carrier wherein said polypeptide comprises SEQ ID NO:4, said polypeptide does not bind to choline, said polypeptide exhibits a tertiary structure as found in a native, full-length CbpA polypeptide, and the polypeptide content of said vaccine being in an amount effective for treating or protecting against R6x pneumococcal infection or Type 4 pneumococcal infection.

16.-37. (Canceled)